Amgen Inc. $AMGN Holdings Lifted by Clear Trail Advisors LLC

Clear Trail Advisors LLC increased its position in shares of Amgen Inc. (NASDAQ:AMGN) by 18.4% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 9,539 shares of the medical research company’s stock after acquiring an additional 1,480 shares during the period. Clear Trail Advisors LLC’s holdings in Amgen were worth $3,356,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. Dogwood Wealth Management LLC raised its holdings in shares of Amgen by 275.0% in the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after purchasing an additional 55 shares in the last quarter. Anfield Capital Management LLC boosted its holdings in Amgen by 1,000.0% during the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after buying an additional 70 shares in the last quarter. Board of the Pension Protection Fund bought a new stake in Amgen during the fourth quarter worth approximately $26,000. Manning & Napier Advisors LLC grew its position in Amgen by 49.2% in the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock worth $32,000 after buying an additional 32 shares during the last quarter. Finally, Olistico Wealth LLC acquired a new position in Amgen in the fourth quarter worth approximately $33,000. 76.50% of the stock is currently owned by institutional investors.

Amgen Stock Performance

Shares of AMGN opened at $344.72 on Tuesday. The company’s 50 day moving average price is $340.50 and its 200 day moving average price is $345.86. Amgen Inc. has a 52 week low of $267.83 and a 52 week high of $391.29. The company has a market capitalization of $186.05 billion, a PE ratio of 23.99, a PEG ratio of 3.39 and a beta of 0.42. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The firm had revenue of $8.62 billion for the quarter, compared to analyst estimates of $8.58 billion. During the same quarter in the prior year, the business earned $4.90 EPS. The company’s revenue for the quarter was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Research analysts expect that Amgen Inc. will post 22.38 EPS for the current fiscal year.

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the company’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the transaction, the senior vice president directly owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. This represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.85% of the company’s stock.

Wall Street Analyst Weigh In

AMGN has been the subject of a number of recent research reports. Truist Financial increased their price objective on Amgen from $325.00 to $327.00 and gave the company a “hold” rating in a research report on Friday, May 1st. Piper Sandler reissued an “overweight” rating on shares of Amgen in a research note on Friday, June 12th. Leerink Partners restated a “market perform” rating and issued a $355.00 target price on shares of Amgen in a report on Thursday, March 5th. Morgan Stanley boosted their target price on Amgen from $332.00 to $340.00 and gave the stock an “equal weight” rating in a research report on Tuesday, June 9th. Finally, Weiss Ratings reaffirmed a “buy (b)” rating on shares of Amgen in a report on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, fifteen have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, Amgen presently has an average rating of “Hold” and a consensus target price of $354.42.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.